Drug Safety
Risk minimisation measures (RMMs) are a key issue for better care and Bahri and colleagues’ plan to enhance the dialogue between regulators, health care professionals (HCPs) and patients at the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) with a Stakeholder Safety Engagement Tool is welcome [1]